Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fidler Sarah, Fox Julie, Tipoe Timothy, Longet Stephanie, Tipton Tom, Abeywickrema Movin, Adele Sandra, Alagaratnam Jasmini, Ali Mohammad, Aley Parvinder K, Aslam Suhail, Balasubramanian Anbhu, Bara Anna, Bawa Tanveer, Brown Anthony, Brown Helen, Cappuccini Federica, Davies Sophie, Fowler Jamie, Godfrey Leila, Goodman Anna L, Hilario Kathrine, Hackstein Carl-Philipp, Mathew Moncy, Mujadidi Yama F, Packham Alice, Petersen Claire, Plested Emma, Pollock Katrina M, Ramasamy Maheshi N, Robinson Hannah, Robinson Nicola, Rongkard Patpong, Sanders Helen, Serafimova Teona, Spence Niamh, Waters Anele, Woods Danielle, Zacharopoulou Panagiota, Barnes Eleanor, Dunachie Susanna, Goulder Philip, Klenerman Paul, Winston Alan, Hill Adrian V S, Gilbert Sarah C, Carroll Miles, Pollard Andrew J, Lambe Teresa, Ogbe Ane, Frater John
Аннотация
METHODS: Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed 12 months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µL. Immune responses to the ancestral strain and variants of concern were measured by anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, activation induced marker (AIM) assay, and T-cell proliferation.
FINDINGS: In total, 54 participants received 2 doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) 1 year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titers (MSD), ACE-2 inhibition, and IgG ELISA results were significantly higher compared to Day 182 titers (P < .0001 for all 3). SARS-CoV-2 specific CD4+ T-cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4+ and CD8+ T-cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron.
CONCLUSIONS: In PWH receiving a third vaccine dose, there were significant increases in B- and T-cell immunity, including to known variants of concern (VOCs).